Trials / Completed
CompletedNCT03402438
Renal Impairment Study
Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
The study will investigate the pharmacokinetics of BAY1142524 in subjects with mild to severe renal impairment compared to age; weight, and gender-matched healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fulacimstat (BAY1142524) | single oral dose of 25 mg immediate-release tablet BAY1142524 |
Timeline
- Start date
- 2018-02-12
- Primary completion
- 2018-12-04
- Completion
- 2019-03-19
- First posted
- 2018-01-18
- Last updated
- 2020-03-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03402438. Inclusion in this directory is not an endorsement.